Reuters

Emergent Bio's smallpox vaccine gets US approval for mpox

Aug 30 (Reuters) - The U.S. Food and Drug Administration granted expanded approval to Emergent BioSolutions' (EBS.N), opens new tab smallpox vaccine for use in people at high risk of mpox infection.
Science Daily

Potential single-dose smallpox and mpox vaccine moves forward

An FDA-approved vaccine for smallpox and mpox is effective but causes side effects. The other requires multiple doses. An experimental single-dose vaccine uses the horsepox virus to harness the ...
Independent Record

Bush administration preparing for a national smallpox vaccination effort

‘Pre-attack’ plan must account for numerous health risks of vaccine. WASHINGTON — Looming war with Iraq and growing concern over the threat of bioterrorism are moving federal officials to consider ...
Seeking Alpha

Emergent stock jumps as FDA clears smallpox vaccine for people at high risk of mpox

Emergent BioSolutions (NYSE:EBS) shares jumped over 23% premarket on Friday as the U.S. Food and Drug Administration (FDA) approved expanded use of the company’s ACAM2000 smallpox vaccine to include ...